Novartis dials down RNA research

Share this article:

Novartis is scaling down its push to develop RNA therapies. BioCentury reports that the drugmaker plans to “maintain a small group in the field and will look into partnering opportunities” but will “significantly reduce” its internal focus.

According to BioCentury, the drugmaker said RNA treatments look to be a narrow field and that the company expects to lay off some of the 26 employees dedicated to RNA research.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.